SAVA Jan 2025 40.000 put
| Previous close | 22.58 |
| Open | 22.58 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 40.00 |
| Expiry date | 2025-01-17 |
| Day's range | 22.58 - 22.58 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireCassava Sciences to Present at the Jefferies Global Healthcare Conference
AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that its management has been invited to present at the Jefferies Global Healthcare Conference in New York City. When:Thursday, June 8th at 4:30 pm Eastern timeLive Webcast:https://wsw.com/webcast/jeff281/sava/1846130Archived Replay:https://www.CassavaSciences.com/company-presentations About SimufilamSimufilam is Cassava Sci
ZacksCassava (SAVA) Up on Progress With Alzheimers Disease Study
Cassava (SAVA) made positive progress with simufilam, an oral drug treatment for Alzheimer's disease dementia. The company's shares gain in the last month.
Motley FoolWhy Shares of Cassava Sciences Jumped This Week
Cassava Sciences finished dosing in one of its phase 3 trials for its Alzheimer's therapy Simufilam.
- GlobeNewswire
Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer’s Disease
The Cognition Maintenance Study (CMS) is a 6-month, Randomized Controlled Trial of Simufilam in Over 125 Patients with Alzheimer’s Disease.Primary Outcome Measures Are Safety and Change in Cognition Scores.Top-line Clinical Results of the CMS Are Expected in Q3 2023. AUSTIN, Texas, May 11, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced the completion of patient dosing in a 6-month, randomized controlled trial of simufilam i
- GlobeNewswire
New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A
New in vitro data from Europe show that simufilam can reverse altered filamin A protein (FLNA) in pituitary tumor cells, leading to improved cell signaling.Data suggest FLNA is a central factor influencing pituitary tumor cell behavior. Data to be presented at the European Society of Endocrinology, May 13-16th. AUSTIN, Texas, May 08, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced new data from European researchers that high
- GlobeNewswire
Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates
Over 1,244 Alzheimer’s patients now enrolled in Phase 3 studies of simufilam.Completion of patient enrollment for Phase 3 program still expected Q4 2023.$187.5 Million Cash and Cash Equivalents at March 31, 2023. AUSTIN, Texas, May 01, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2023. Net loss was $24.3 million, or $0.58 per share, com
- GlobeNewswire
Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference
AUSTIN, Texas, April 26, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that Remi Barbier, President & Chief Executive Officer, has been invited to present at the 2023 H.C. Wainwright BioConnect Investor Conference in New York. In addition, management will be available for one-on-one meetings with institutional investors who are registered to attend this conference. When: Tuesday, May 2nd at 3
Simply Wall St.The three-year returns have been massive for Cassava Sciences (NASDAQ:SAVA) shareholders despite underlying losses increasing
While Cassava Sciences, Inc. (NASDAQ:SAVA) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 22%...
- GlobeNewswire
Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates
In Q2 2023, We Expect to Complete Patient Dosing for our Cognition Maintenance Study in Alzheimer’s disease.In Q3 2023, We Expect to Announce Results of our Cognition Maintenance Study.In Q4 2023, We Expect to Complete Patient Enrollment for our Phase 3 Studies of Simufilam in Alzheimer’s disease.Mid-year 2023, We Expect an Independent Third Party to Present Evidential Data for The Biological Activity of Simufilam Outside of Neurodegeneration.Cash And Cash Equivalents Were $201 Million at Decemb
- GlobeNewswire
Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
953 Alzheimer’s Patients Are Now Enrolled Across Phase 3 Studies Both Phase 3 Studies Have Passed the Halfway Mark for Enrollment Goal Is to Complete Enrollment for Both Phase 3 Studies by Year-End 2023 AUSTIN, Texas, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced an update on patient enrollment for its on-going Phase 3 clinical studies of simufilam for the treatment of Alzheimer’s disease dementia. Simufilam, an o
Motley Fool3 Big Reasons to Sell Cassava Sciences Stock Right Now
On any list of biotech plays that might multiply in value in a relatively short period, Cassava Sciences (NASDAQ: SAVA) is likely to be near the top of the list. It's exploring whether its drug called simufilam is safe and effective to treat early-stage Alzheimer's disease, though its clinical trials have (so far) shed little light on the issue. The biggest reason to sell Cassava stock: After an open-label phase 2 clinical trial of simufilam, the market reacted quite negatively to the release of new data that management spun as being positive.
GlobeNewswireCassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
Figure 1 Statistical model of historical 1-year declines on ADAS-Cog, placebo vs simufilam treatment, mild-to-moderate disease.¹ Figure 2 Statistical model of historical 1-year declines on ADAS-Cog, placebo vs simufilam treatment, in early disease and mild disease.² ADAS-Cog mean scores changed minimally over 1 year in patients with mild-to-moderate Alzheimer’s disease treated with open-label simufilam tablets.47% of patients improved on ADAS-Cog over 1 year, and this group improved by 4.7 point
ZacksIs Mesa Laboratories (MLAB) Outperforming Other Medical Stocks This Year?
Here is how Mesa Labs (MLAB) and Cassava Sciences, Inc. (SAVA) have performed compared to their sector so far this year.
- Simply Wall St.
Cassava Sciences, Inc. (NASDAQ:SAVA) most popular amongst individual investors who own 69% of the shares, institutions hold 25%
If you want to know who really controls Cassava Sciences, Inc. (NASDAQ:SAVA), then you'll have to look at the makeup of its share registry...
- GlobeNewswire
Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD
AUSTIN, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) announced today that a valued and long-time member of the Company, Nadav Friedmann, PhD, MD, has died following a brief journey with cancer, only recently discovered. “We mourn profoundly the passing of a cherished colleague and friend,” said Remi Barbier, President and CEO. “For over 20 years, he generously gave his talents, expertise and integrity in support of our success. On behalf of our employees and our
- GlobeNewswire
Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease
Outside Biostatisticians with Specific Expertise in Alzheimer’s Disease Will Conduct an Independent Statistical Analysis on The Clinical Dataset. Clinical Dataset May Be Announced Approximately Year-End 2022, Pending Completion of Study Report by Outside Biostatisticians. AUSTIN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced the completion of drug administration in an open-label study of simufilam for Alzhe
- GlobeNewswire
Cassava Sciences Announces Closing of $50 Million Registered Direct Offering
AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of its previously announced registered direct offering of 1,666,667 shares of its common stock, at a purchase price per share of $30, for gross proceeds of approximately $50 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. JonesTrading
- GlobeNewswire
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
AUSTIN, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has entered into a definitive agreement with several healthcare-focused and other institutional investors for the purchase of 1,666,667 shares of its common stock, at a purchase price of $30 per share, for gross proceeds of approximately $50 million, in a registered direct offer
Yahoo Finance VideoCassava Sciences stock pops after rival experiences setback in Alzheimer’s research
Shares of Cassava are moving higher on news that its rival Roche suffered a setback in its Alzheimer's drug research trial.
- GlobeNewswire
Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates
– $174.7 Million Cash and Cash Equivalents at September 30, 2022 – – Over 650 Patients Now Enrolled in Phase 3 Program - – New Clinical Data for Simufilam in Alzheimer’s Disease Expected – AUSTIN, Texas, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the third quarter ended September 30, 2022 and provided a clinical update on its Phase 3 clinical program of simuf
- GlobeNewswire
Cassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” Campaign
AUSTIN, Texas, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced that it has filed a lawsuit in federal court against certain individuals who executed a “short and distort” campaign against the Company. The 150+ page complaint alleges that the Defendants’ disinformation campaign caused a precipitous decline in Cassava Sciences’ stock price, a multi-billion dollar decline in its market capitalization, and delayed the C
ZacksCassava Sciences (SAVA) to Report Q3 Earnings: What's in Store?
Cassava Sciences (SAVA) is expected to provide an update on its pipeline candidates during its third-quarter earnings.
ZacksCassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $36.44, moving -0.87% from the previous trading session.
- GlobeNewswire
Cassava Sciences Announces Expansion of Leadership Team
Chris Cook, A Skilled Litigator, To Join Management Team as General CounselNew Position Is Expected to Be Critical to Operations and Strategic Initiatives AUSTIN, Texas, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced the expansion of its leadership team with the appointment of Christopher Cook as Senior Vice President and General Counsel. This is a newly created position, reporting to Remi
ZacksCassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $34.31, moving +0.7% from the previous trading session.